Company Overview - Agios Pharmaceuticals is a clinical-stage biopharmaceutical company focused on therapies for rare genetic diseases related to cellular metabolism [6][7] - The company has a marketed product, PYRUKYND (mitapivat), for hemolytic anemias and a pipeline candidate, AG-946, currently in Phase I clinical trials [7] - As of February 13, 2026, Agios shares were priced at $27.96, with a market capitalization of $1.63 billion and a revenue of $54.03 million over the trailing twelve months [4][6] Recent Developments - Rock Springs Capital Management sold 159,379 shares of Agios Pharmaceuticals in Q4 2025, with an estimated transaction value of $5.59 million [1][2] - Following this sale, Rock Springs' position in Agios was valued at $21.75 million, a decrease of $16.72 million from the previous period, reflecting both trading and market price changes [2][10] - The fund's stake in Agios now represents 1.12% of its reported assets under management (AUM), down from 2.2% in the prior quarter [6][10] Market Performance - Agios shares have declined by 16.0% over the past year, underperforming the S&P 500 by 27.8 percentage points [6][10] - The stock price fell significantly after the Phase 3 RISE UP trial of mitapivat met its hemoglobin endpoint but failed to reduce sickle cell pain crises, leading to a 50% drop in November 2025 [9][10] Strategic Focus - Agios targets patients with rare blood disorders, primarily focusing on healthcare providers, specialty clinics, and institutions treating hemolytic anemias [7][8] - The company's strategy emphasizes advancing innovative treatments for underserved patient populations, which supports its competitive position in the biotechnology sector [8]